Whittaker, Steven R.

Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics

Advanced Breast Cancer TherapiesCancer-related Molecular Pathways

Cited by 384

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma

Girotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., et al. (2015) · Cancer Cell

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 212

Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells

Delgado-Goñi, T., Galobart, T. C., Wantuch, S., Normantaite, D., Leach, M. O., Whittaker, S. R., & Beloueche-Babari, M. (2020) · British Journal of Cancer

Melanoma and MAPK PathwaysCancer, Lipids, and Metabolism

Cited by 39